What is Insomnia? What Causes Insomnia? Insomnia, from the Latin "in" (not) and "somnus" (sleep), is a condition characterized by difficulty falling asleep and remaining asleep. It includes a broad spectrum of sleep disorders, from lack of quantity of sleep to lack of quality of sleep. Insomnia is often separated into three types. Transient insomnia occurs when symptoms last from a few days to a few weeks.
Source: www.medicalnewstoday.comNew Body Of Research Suggests Statin Use Benefits Multiple Areas Of Urologic Health Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins--commonly prescribed to lower cholesterol--may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS). Several key research studies highlighting these benefits will be presented during a special panel for the media on Monday, April 27 from 9 to 10:30 a.m.
Source: www.medicalnewstoday.comVIVUS Initiates Open Label Safety Study Of Avanafil For Erectile Dysfunction VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED).
Source: www.medicalnewstoday.comStudy Reported Tadalafil Taken Once Daily Improved Erectile Function In Men With ED And Sexual Quality Of Life In Couples Eli Lilly and Company (NYSE: LLY) announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-tolerated, improved erectile function for men with erectile dysfunction (ED) and reported improvement in the sexual quality of life scores for men and their female partners.
Source: www.medicalnewstoday.comNew Scientific Data On ADHD Treatments Presented By Shire At National Psychiatric Scientific Meeting Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (CII) and investigational non-scheduled guanfacine extended release, at a national scientific meeting of psychiatrists being held May 16 -21 in San Francisco, CA.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 PM
